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Abstract 
Lung ultrasound surface wave elastography (LUSWE) is a 
novel noninvasive technique for measuring superficial lung 
tissue stiffness. The purpose of this study was to translate 
LUSWE for assessing patients with interstitial lung disease 
(ILD) and various connective diseases including systemic 
sclerosis (SSc). In this study, LUSWE was used to measure the 
surface wave speed of lung at 100 Hz, 150 Hz and 200 Hz 
through six intercostal lung spaces for 91 patients with ILD 
and 30 healthy control subjects. In addition, skin viscoelasticity 
was measured at both forearms and upper arms for patients 
and controls. The surface wave speeds of patients’ lungs were 
significantly higher than those of control subjects for the six 
intercostal spaces and the three excitation frequencies. Patient 
skin elasticity and viscosity were significantly higher than those 
of control subjects for the four locations on the arm. In 
dividing ILD patients into two groups, ILD patients with SSc 
and ILD patients without SSc, significant differences between 
each patient group with the control group were found for both 
the lung and skin. No significant differences were found 
between the two patients group, although there were some 
differences at a few locations and at 100 Hz. LUSWE may be 
useful for assessing ILD and SSc and screening early stage 
patients.  
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I.     INTRODUCTION 
         Ultrasonography is not widely used for clinically 
assessing lung disease. Lung tissue is normally filled with 
air, and the difference in acoustic impedance between air 
and lung parenchyma is large. Most of the energy of the 
ultrasound wave is reflected from the lung surface. 
Ultrasonography evaluation of the thorax is therefore 
limited to evaluating structures outside of the lung such as 
pleural fluid, thoracic superficial masses, or adenopathy [1]. 
However, lung ultrasonography is the standard for 
diagnosing pleural diseases and is very useful in the 
emergency and critical care settings [2, 3]. Lung ultrasound 
imaging typically presents artifacts such as A-lines and B-
lines and features such as lung sliding and lung point [3]. 
These artifacts and features may be used to assess various 
lung disorders including lung fibrosis [4], pneumothorax 
[5], and lung consolidations [6]. However, analysis of B-line 
artifacts is qualitative and relies on visual interpretation 
which subjects to inter-operator variability [7]. 
          We have developed a lung ultrasound surface wave 
elastography (LUSWE) technique to measure superficial 
lung tissue stiffness safely and quickly [8-11]. In LUSWE, a 
0.1 second harmonic vibration at a given low frequency is 
generated by the indenter of a handheld vibrator on the chest 
wall of a subject. The ultrasound probe is positioned about 5 
mm away from the indenter in the same intercostal space to 
measure the generated surface wave propagation on the lung 
in that intercostal space. The measurement of surface wave 
speed on the lung is determined from the change in wave 
phase with distance and independent of the location of wave 
excitation.  
         We are evaluating LUSWE for assessing patients with 
interstitial lung disease (ILD) in a prospective clinical 
research study. Patients with ILD have fibrotic and stiff 
lungs leading to symptoms, especially dyspnea, and may 
eventually lead to respiratory failure [12]. Many ILDs 
typically are distributed in the peripheral, subpleural regions 
of the lung [13, 14]. The superficial distribution of lung 
fibrosis is especially suited for LUSWE. Diagnosis of lung 
fibrosis can be difficult, especially early in the disease 
course, because the symptoms are nonspecific (most 
commonly shortness of breath and a dry cough) [2, 4, 15]. 
High-resolution computed tomography (HRCT) is the 
clinical standard for diagnosing lung fibrosis [16, 17], but it 
substantially increases radiation exposure for patients. 
Various HRCT scanning techniques were proposed to 
reduce the dose [18]. Lung fibrosis results in stiffened lung 
tissue. However, HRCT does not directly measure lung 
stiffness.  
Both ILD and systemic sclerosis (SSc) are systemic 
diseases. SSc is a multi-organ connective tissue disease 
characterized by immune dysregulation and organ fibrosis 
[19]. Skin involvement in SSc, the major clinical feature, 
can span from edematous swelling and induration to 
extensive fibrosis and eventually atrophy. SSc is categorized 
by variable extent and severity of skin thickening and 
hardening. The degree of skin involvement is an important 
measure and predictor of mortality [20]. Severe organ 
involvement, especially of the skin and lungs, is the cause of 
morbidity and mortality in SSc [21]. Improvement in skin 
stiffness is associated with improved survival in many 
clinical trials [22].  
          There is a close relationship between lung and skin 
involvements in both diseases. Patients with SSc have a high 
incidence of lung fibrosis [19, 23]. Skin and lung fibrosis 
are prominent features of SSc [19, 24]. A large study 
showed that 35% of patients with SSc had lung fibrosis and 
15% had pulmonary hypertension [23]. Survival rates of 
patients with SSc-ILD, connective tissue disease–associated 
ILD, and idiopathic pulmonary fibrosis were studied [25]. 
Patients with SSc-ILD had better survival rates than those 
with other ILDs, which was potentially at least partly 
attributable to routine screening and early detection of ILD 
in patients with SSc. A multidisciplinary assessment of 
patients with SSc-ILD may lead to improved diagnosis and 
management [26, 27].  
The Modified Rodnan Skin Score (MRSS) is the 
standard skin assessment tool in the majority of clinical 
studies of SSc [28]. It shows that patients with improved 
MRSS after two years of treatment had improved survival 
[22]. The MRSS is commonly used as an outcome measure 
in clinical trials [29]. However, the MRSS is a palpation 
method, which is subjective, and thus, its accuracy is user-
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dependent [30]. Moreover, it is difficult to measure the 
change of skin stiffness over time using palpation [31].  
Lung involvement in patients with SSc may be 
predicted at early stages by evaluation of skin fibrosis 
because skin manifestation is an early and easily detectable 
marker of SSc disease activity. Recommendations for future 
clinical trials stress the critical need for noninvasive, 
clinically applicable biomarkers to improve the evaluation 
of patients with SSc-ILD [32]. In this paper, we report our 
results on both lung and skin stiffness measurements using 
LUSWE on 91 patients with ILD and 30 healthy control 
subjects. 
 
METHOD 
Lung ultrasound surface wave elastography (LUSWE) 
technique 
          In LUSWE, a 0.1s harmonic vibration at a frequency 
is generated on the skin of the chest wall in an intercostal 
space. The resulting wave propagation at that frequency 
travels through the intercostal muscle and propagates on the 
surface of the lung. The wave motions on the selected 
locations on the lung surface are noninvasively measured 
using our ultrasound-based method [33]. The phase change 
with distance of the harmonic wave propagation on the lung 
surface is analyzed, and from which the surface wave speed 
is measured, 
                        2 /= ∆ ∆sc f rπ f ,                                 (1) 
where ∆r  is the distance of two measuring locations, ∆f  
is the wave phase change over distance, and f is the 
frequency. 
The measurement of wave speed can be improved 
by using multiple phase change measurements over 
distances. The regression of the phase change ∆f  with 
distance ∆r  can be obtained by “best fitting” a linear 
relationship between them, and the equation is 
      ¶∆ = ∆ +rf α β ,                                   (2) 
where ¶∆f  denotes the value of ∆f  on the regression for a 
given distance of ∆r , and α is the regression parameter. 
The surface wave speed can be estimated by 
¶2 / 2 /src f r fπ f π α= ∆ ∆ = ,                          (3) 
where src is the estimation of wave speed from the 
regression analysis. 
           The surface wave speed can be related to the elastic 
modulus of tissue as [34], 
1
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where µ is the shear elasticity in Pascals and ρ is the mass 
density of the tissue in kg/m3.  
For soft tissue under low frequency harmonic 
excitation, Voigt’s model, which consists of a spring of 
elasticity µ1 and a damper of viscosity µ2 connected in 
parallel, has been proven to be effective in modeling the 
linear viscoelastic materials [35-38]. The wave dispersion 
curve of wave speed cs with respect to the excitation 
frequency ω can be formulated by, 
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          Measurement of lung surface wave speed is 
noninvasive. Representative LUSWE analysis for a patient 
is shown in Figure 1(a). The wave motions are measured at 
eight locations on the lung surface. The normal component 
of the lung surface motion can be analyzed by cross-
correlation analysis of the ultrasound tracking beams [39, 
40]. In this study, eight locations over a length of 
approximately 10 mm on the lung surface were used to 
measure the normal component of the lung surface motion. 
The tissue motion is measured at these locations in response 
to the harmonic wave excitation on the chest wall. A high 
pulse repetition rate of 2000 pulse/s is used to detect tissue 
motion in response to the wave excitation at 100, 150, or 
200 Hz. A Verasonics ultrasound system (Verasonics, Inc; 
Kirkland, WA) is used that collects up to a few thousand 
imaging frames per second by using a plane-wave pulse 
transmission method. 
Figure 1. (a) Representative LUSWE analysis for a patient 
subject. The wave motions are measured at eight locations 
on the lung surface. (b) The wave phase delay of the 
remaining locations, relative to the first location, is used to 
measure the surface wave speed. 
 
          The surface wave speed on the lung is estimated by 
determining the change in wave phase with distance along 
the lung surface. The lung motion at the first location is 
measured and used as a reference. The wave phase delay of 
the lung motions at the remaining locations, relative to the 
reference at the first location, is used to measure lung 
surface wave speed. The surface wave speed is estimated by 
the phase changes simultaneously at the 8 locations. Figure 
1(b) shows a representative wave speed at 100 Hz for the 
patient in the left second intercostal space. The surface wave 
speed was 3.29 ± 0.21m/s (mean ± standard error from the 
  
(a) (b) 
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regression analysis) at 100 Hz for the patient. The wave 
speed on the lung surface is determined by analyzing 
ultrasound data directly from the lung. Therefore, the wave 
speed measurement is local and independent of the location 
and amplitude of excitation. 
 
Skin measurements 
This noninvasive technique can be used to measure 
viscoelastic properties of other tissues. In this research, we 
also measured the surface wave speed of skin on the arms at 
the three excitation frequencies for patients and controls. In 
skin testing, an ultrasound gel pad standoff by Aquaflex® 
(Parker Laboratories, Inc., Fairfield, NJ 07004, USA) was 
placed between the ultrasound probe and the skin to 
improve the imaging quality of skin. The vibration 
excitation was directly applied on the skin. 
 
Patient and healthy control subjects 
          Human studies were approved by the Mayo Clinic 
Institutional Review Board (IRB). Each participant 
completed an informed consent form. Patients were enrolled 
in this research based on their clinical diagnoses. 91 patients 
with ILD were enrolled from Mayo Clinic Departments of 
Rheumatology and Pulmonary and Critical Care Medicine. 
These patients were confirmed ILD patients with clinical 
assessments together with pulmonary function test and high 
resolution CT scans. These ILD patients also had various 
diseases including systemic sclerosis (SSc) or scleroderma, 
rheumatoid arthritis, connective tissue disease, idiopathic 
pulmonary fibrosis, anti-synthetase, Sjögren’s syndrome, 
polymyositis, and systemic lupus erythematosus.  
         We intended to study the relationship between ILD 
and SSc by measuring both lung and skin. We divide the 
patients into two groups, patients with SSc (41 patients) and 
patients without SSc (50 patients). Patients with SSc were 
diagnosed according to the American College of 
Rheumatology (ACR) criteria [41]. The ACR classification 
criteria for diagnosing SSc requires either 1) the major 
criterion of proximal scleroderma as judged by palpating or 
simply observing the skin; or 2) 2 minor criteria such as 
sclerodactyly, digital pitting scars, or loss of substance from 
the finger pad, and bibasilar pulmonary fibrosis. Patients’ 
mean age was 62.4 ± 13.0 years (range 20-85, 39 male and 
52 female). 30 healthy subjects were enrolled as controls if 
they did not have any lung and skin diseases. Controls’ 
mean age was 45.4 ± 14.1 years (range 22-73, 14 male and 
16 female). 
 
Human study protocol 
          The subject is tested in a sitting position. The 
subject’s lung is tested first and then the skin. It takes about 
30-40 minutes to finish the testing. Both lungs of the subject 
are tested through six intercostal spaces. The upper anterior 
lungs are tested at the second intercostal space in the mid-
clavicular line. The lower lateral lungs are tested at one 
intercostal space above the level of the diaphragm in the 
mid-axillary line. The lower posterior lungs are tested at one 
intercostal space above the level of the diaphragm in the 
mid-scapular line. Ultrasound imaging is used to identify the 
lungs and select appropriate intercostal spaces to measure 
the upper and lower lungs. A 0.1-second harmonic vibration 
is generated by the indenter of the handheld shaker (Model: 
FG-142, Labworks Inc., Costa Mesa, CA 92626, USA) on 
the chest wall. The excitation force from the indenter is 
much less than 1 Newton and the subject only feels a small 
vibration on his/her skin. The indenter of the handheld 
shaker is placed on the chest wall in an intercostal space. 
The ultrasound probe is positioned about 5 mm away from 
the indenter in the same intercostal space to measure the 
resulting surface wave propagation on the lung. An 
ultrasound probe L11-4 with a central frequency of 6.4 MHz 
is positioned about 5 mm away from the indenter in the 
same intercostal space to measure the resulting surface wave 
propagation on the lung. A Verasonics ultrasound system 
(Verasonics V1, Verasonics, Inc., Kirkland, WA 98034, 
USA) is used in this research. Images of the lung and skin 
are acquired by compounding 11 successive angles at a 
pulse repetition frequency (PRF) of 2 kHz. The lung is 
tested at total lung capacity when the subject takes a deep 
breath and holds for a few seconds. The surface wave 
speeds are measured at three excitation frequencies of 100 
Hz, 150 Hz, or 200 Hz. Three measurements are performed 
at each location and at each frequency. A small tissue 
motion in tens of µm is enough for sensitive ultrasound 
detection of the generated tissue motion. The 100 Hz wave 
motion is stronger than those of higher frequency waves. 
The higher frequency waves have smaller wave length but 
decay more rapidly over distance than the lower frequency 
waves. The frequency ranges chosen in this study consider 
the wave motion amplitude, spatial resolution, and wave 
attenuation. The same ultrasound system and probe are used 
for skin testing. The subject’s arm is placed horizontally on 
a pillow in a relaxed state. The skin of both left and right 
forearms and upper arms of subjects are tested. These 
locations are in the central part of the arms and on the dorsal 
sides.  
 
Statistical analysis 
An unpaired, two-tailed t-test between the patients 
and healthy control subjects was conducted to compare the 
sample means. Differences in mean values were considered 
significant when p<0.05. A one-way ANOVA with critical p 
value = 0.05 and a post hoc Tukey test with α = 0.05 was 
conducted to compare the sample means among three 
groups: ILD patients with SSc, ILD patients without SSc 
and healthy control subjects.  
 
RESULTS 
A comparison of wave speeds of lung surface 
between 91 ILD patients and 30 healthy control subjects is 
shown in Figure 2 for 100 Hz, 150 Hz, and 200 Hz. The 
three intercostal spaces are designated by a number from 1 to 
3. The upper anterior lung is designated by 1. The lower 
lungs at the lateral and posterior positions are designated by 
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2 and 3, respectively. The right and left lungs are designated 
by letters R and L, respectively. Therefore, L1 represents the 
left anterior lung in the second intercostal space. The p-
values for the t -test were less than 0.0001 for all intercostal 
spaces and for three frequencies between the patients and 
controls, respectively.       
 
(a) 
 
(b) 
 
(c) 
Figure 2. Comparison of wave speeds between patients and 
healthy control subjects through six intercostal spaces. 
Surface wave speeds were measured at (a) 100 Hz, (b) 150 
Hz, and (c) 200 Hz.  
 
Figure 3 shows the comparison of elasticity and 
viscosity of skin between 91 ILD patients and 30 healthy 
control subjects. Viscoelasticity is estimated using equation 
(5) with wave speed measurements at 100 Hz, 150 Hz, and 
200 Hz. Most soft tissues have a mass density close to 1.0 
g/cm3. In this paper, the mass density of skin is assumed to 
be 1.0 g/cm3. The forearm and upper arm are designated by 
numbers 4 and 5, respectively. The right and left arms are 
designated by letters R and L, respectively. Therefore, R4 
represents the skin of the right forearm. The p-values for the 
t -test were less than 0.0001 for the four locations between 
patients and controls. Therefore, the magnitudes of both 
elasticity and viscosity of patients were statistically higher 
than those of healthy subjects.  
 
(a) 
 
(b) 
Figure 3. Comparison of elasticity µ1 (a) and viscosity µ2 
(b) between patients and healthy control subjects at four 
locations.  
 
One purpose of the research was to study if the 
relationship between the lung stiffness and the skin stiffness 
could be identified for patients with ILD or SSc. Both ILD 
and SSc are systemic diseases. We divide the patients into 
two groups. Group 1 is the ILD patients with SSc, and group 
2 is the ILD patients without SSc. We analyze the date for 
these two groups of patients and the control subjects. 
Figure 4 shows the one-way ANOVA analyses of 
surface wave speeds of lung for 100 Hz, 150 Hz, and 200 
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Hz among the three groups: ILD patients with SSc, ILD 
patients without SSc, and healthy controls.. Table 1 shows 
the statistical results of lung for the three group subjects at 
the three frequencies and the six intercostal spaces. The p-
values for the one-way ANOVA test were less than 0.05 for 
all intercostal spaces and for three frequencies among the 
three groups. The post hoc Tukey test was performed after 
ANOVA to analyze the subgroups. Significant differences of 
wave speed between either group 1 patients or group 2 
patients with controls were found. No significant differences 
were found between the group 1 patients and the group 2 
patients for most locations and three frequencies. However, 
there are statistically significant differences at 100 Hz for 
locations L1 (p = 0.003), R1 (p = 0.002) and R3 (p = 0.001) 
between group 1 patients and group 2 patients. There is 
significant difference at 150 Hz for location R1 (p = 0.026) 
between group 1 patients and group 2 patients. These 
findings are interesting because ILD affect more on lower 
lungs but less on upper lungs at L1 or R1. Although we can 
generally conclude that there are no significant differences 
of wave speed between ILD patients with SSc and ILD 
patients without SSc. The upper lungs and low frequencies 
may provide more information to separate the two group 
patients. 
 
(a) 
 
(b) 
 
(c) 
Figure 4. Comparison of wave speeds between patients with 
SSc, patients without SSc, and healthy control subjects 
through six intercostal spaces. Surface wave speeds were 
measured at (a) 100 Hz, (b) 150 Hz, and (c) 200 Hz.  
 
Table 1. Statistical results of lung surface wave speeds for 
the three group subjects at the three frequencies and six 
intercostal spaces. The three groups are patients with SSc, 
patients without SSc, and healthy control subjects.  
 
 
Figure 5 shows the one-way ANOVA analyses of 
elasticity and viscosity of skin among the three groups. 
Table 2 shows the statistical results of skin for the three 
group subjects at the four locations on the arm. The p-values 
for the one-way ANOVA test were less than 0.05 for all 
locations among the three groups. The post hoc Tukey tests 
indicated that significant differences of elasticity or viscosity 
between either group 1 patients or group 2 patients with 
controls were found. In addition, no significant differences 
were found between the group 1 patients and the group 2 
patients for most locations. There is one significant 
difference in viscosity at R4 (p = 0.019) between group 1 
patients and group 2 patients. We may generally conclude 
that there are no significant differences of skin elasticity and 
viscosity between ILD patients with SSc and ILD patients 
without SSc. Some locations such as R4 may be useful to 
separate the two group patients. 
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(a) 
 
(b) 
 
Figure 5. Comparison of elasticity µ1 (a) and viscosity µ2 
(b) between patients with SSc, patients without SSc, and 
healthy control subjects at four locations.  
 
Table 2. Statistical results of skin elasticity µ1 and viscosity 
µ2 for the three group subjects at the four locations on the 
arm. 
 
 
DISCUSSION 
        LUSWE is a safe technique. Shear wave elastography 
(SWE) techniques use ultrasound radiation force (URF) to 
generate tissue motion. However, URF may not be applied 
to some tissues such as the lung because the relatively high-
intensity ultrasound energy may cause alveolar hemorrhage 
or lung injury [42]. In addition, long period of ultrasound 
pulses with relatively high-intensity ultrasound energy may 
cause damage to the ultrasound system itself, e.g., high 
voltage drop and probe element damage. In LUSWE, the 
wave generation is safely produced using a gentle 
mechanical vibration on the skin. URF is not used for 
generating the shear or surface waves. Diagnostic ultrasound 
is only used for detection of wave propagation. Therefore, 
LUSWE can be used for the lung [8, 43] and eye [44, 45]. 
        LUSWE is a simple technique for measuring the skin. 
Because URF cannot be generated on surface tissue, a 
standoff ultrasound gel pad is needed for the ultrasound 
probe to generate and measure the waves on the skin. 
However, the standoff pad also decays the URF and 
complicates the URF on the skin. In LUSWE, the 
mechanical excitation is directly applied on the skin and the 
standoff pad is only used to improve imaging of the skin.  
        Optical coherence tomography (OCT) [46] and OCT-
based elastography techniques [47, 48] provide high-spatial 
resolution of skin but cannot measure deep subcutaneous 
tissue. The imaging penetration of OCT in skin can be up to 
1.5 mm [49]. Fibrosis not only affects skin but also 
subcutaneous tissue [50]. LUSWE can measure much deep 
subcutaneous tissue than OCT. In the current setup, 
subcutaneous tissues can be measured to up to 45 mm. 
LUSWE can be used to assess skin, subcutaneous 
connective tissue and muscle in the same test which may be 
useful for assessing these systemic diseases.  
     Diagnosis of ILD can be difficult at early stages 
because a patient’s symptoms such as shortness of breath and 
dry cough are nonspecific. The findings of physical 
examinations are usually nonspecific and chest radiography 
typically shows nonspecific or nondiagnostic findings. 
HRCT is the clinical standard for diagnosing lung fibrosis 
[16, 17], but it is expensive and involves radiation.  
     Because ILD is a systemic disease, patients enrolled in 
this research presented with other various diseases. We are 
most interested in ILD patients with SSc. SSc is a multi-
organ connective tissue disease characterized by immune 
dysregulation and organ fibrosis [19]. Severe organ 
involvement, especially of the skin and lung, is the cause of 
morbidity and mortality in SSc. We divided the ILD patients 
into two groups: ILD patients with SSc (41 patients) and ILD 
patients without SSc (50 patients). Our results demonstrate 
that there are significant differences between either patient 
group with the control group for both lung and skin stiffness. 
There are not significant differences between ILD patients 
with SSc and ILD patients without SSc. However, there are 
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some differences between the two patient groups at the upper 
lungs and at 100 Hz. We plan to study some early stage ILD 
patients or SSc patients without ILD symptoms. LUSWE 
may be useful to screen patients at early stages. Connective 
tissue disease has a high prevalence of ILD, from 7% to 50% 
for rheumatoid arthritis, Sjogren’s syndrome, SSc, and 
inflammatory myopathies [51, 52]. Testing both lung and 
skin may provide more information to identify ILD at earlier 
stage. It takes about 30-40 minutes to finish both lung and 
skin tests in this research. We may significantly reduce the 
testing time if we could identify sensitive intercostal spaces 
and frequencies for assessing specific ILD. However, the 
current testing time is still good for a clinical study. LUSWE 
may be easily integrated into a clinical test. LUSWE can be 
used to quantitatively monitor disease progression for ILD 
patients. We are continuing to follow the 91 ILD patients, 
however, a few ILD patients already passed away.  
            ILD consists of various lung disorders due to 
damage and fibrosis of the lung parenchyma. HRCT is the 
clinical standard for diagnosing and characterizing lung 
fibrosis [16, 17]. Although HRCT provides excellent 
imaging for assessing lung fibrosis, it does not directly 
measure lung stiffness. LUSWE provides noninvasive 
measurement of lung stiffness. LUSWE is a safe, quick and 
relatively cheap technique for lung testing which may be 
used for screening patients. In this research, we provide the 
surface wave speeds at 100 Hz, 150 Hz, and 200 Hz. The 
elasticity and viscosity of the lung can be estimated from 
equation (5) if the lung mass density is known. However, we 
cannot find the data of lung mass density for fibrotic lungs. 
Also, the lung density is dependent on the pulmonary 
pressure. In this research, a subject is tested at total lung 
capacity (TLC) when taking a deep breath and holding. In a 
paper using an x-ray technique [53], lung density was 
averaged to be 0.32 g/cm3 for healthy lungs. The 
measurements were made with the patient sitting either on a 
chair or in bed and breathing quietly. Lung density was 
0.33-0.93 g/cm3 for patients with pulmonary congestion and 
edema. In an ex vivo study on sheep lungs [54], lung density 
of 0.19-0.26 g/cm3 was used. We expect that the lung 
density of ILD would be higher than that of healthy lungs. 
However, there are no data of lung density for ILD patients. 
Lung mass density is directly associated with lung 
pathology. Computed tomography (CT) is the major clinical 
imaging modality for assessing various lung diseases. The 
mechanism of CT is based on the changes of tissue mass 
density, but the CT system uses the Hounsfield unit (HU) 
and not lung density to image the lung. We are developing a 
deep neural network (DNN) model to predict lung mass 
density on lung phantoms based on the LUSWE 
measurements [55]. We will study how to develop and apply 
the DNN models for the patient’s data. 
           LUSWE is used in this study to evaluate ILD, 
because ILD is mostly superficial tissue disease. However, 
LUSWE may be useful for assessing other lung diseases. 
Pulmonary edema is a fundamental feature of congestive 
heart failure and inflammatory conditions such as acute 
respiratory distress syndrome [56]. The presence of 
extravascular lung water (EVLW) predicts a worse 
prognosis in critically ill patients [57] and increased risk of 
death or heart failure readmission [58]. In the presence of 
EVLW, the ultrasound beam finds subpleural interlobular 
septa thickened by edema [59]. The reflection of the 
ultrasound beam produces reverberation artifacts, called “B-
lines” in wet lungs. The features of “B-lines” are used to 
evaluate pulmonary edema [60] and congestive heart failure 
[61]. A recent multicenter trial demonstrated that lung 
ultrasound (LUS) was more sensitive than chest x-ray for 
the diagnosis of cardiogenic pulmonary edema [62]. 
However, analysis of B-line artifacts is qualitative and relies 
on visual interpretation which is subject to inter-operator 
variability [7]. We have started to evaluate LUSWE for 
assessing EVLW on patients with heart failure. 
           We have found significant differences for both lung 
and skin stiffness between the patients and controls. One of 
the reasons may be due to the fact that the patient’s group is 
relative older than the control’s group. We will plan to study 
the control group with older age around 60. 
 
CONCLUSION 
        Lung ultrasound surface wave elastography is a novel 
noninvasive technique for measuring superficial lung tissue 
stiffness. In this study, LUSWE was used to measure both 
lung and skin for 91 patients with ILD and 30 healthy 
control subjects. The surface wave speeds of patients’ lungs 
were significantly higher than those of control subjects for 
the six intercostal spaces and three excitation frequencies. 
Patient skin elasticity and viscosity were significantly higher 
than those of control subjects for the four locations on the 
arm. In dividing ILD patients into two groups, ILD patients 
with SSc and ILD patients without SSc, significant 
differences between each patient group with the control 
group were found for both the lung and skin. No significant 
differences were found between the two patient groups 
although there were some differences at a few locations and 
at 100 Hz. LUSWE may be useful for assessing ILD and 
SSc and screening early stage patients.  
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